JP2024530315A - Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 - Google Patents
Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 Download PDFInfo
- Publication number
- JP2024530315A JP2024530315A JP2024513277A JP2024513277A JP2024530315A JP 2024530315 A JP2024530315 A JP 2024530315A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024530315 A JP2024530315 A JP 2024530315A
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- compound
- ray powder
- powder diffraction
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021115718 | 2021-08-31 | ||
| CNPCT/CN2021/115718 | 2021-08-31 | ||
| PCT/CN2022/116084 WO2023030363A1 (en) | 2021-08-31 | 2022-08-31 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530315A true JP2024530315A (ja) | 2024-08-16 |
| JP2024530315A5 JP2024530315A5 (cg-RX-API-DMAC7.html) | 2025-09-03 |
Family
ID=85410866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513277A Pending JP2024530315A (ja) | 2021-08-31 | 2022-08-31 | Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240317743A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4396180A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024530315A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240054327A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118215660A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022336557A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230314A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311106A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002465A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023030363A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| TW202604488A (zh) | 2024-06-26 | 2026-02-01 | 瑞士商百濟神州I有限責任公司 | 包含索托克拉固體分散體之醫藥調配物及其製備方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021521138A (ja) * | 2018-04-29 | 2021-08-26 | ベイジーン リミテッド | Bcl−2阻害剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2546294T7 (es) * | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| KR101762724B1 (ko) * | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-08-31 MX MX2024002465A patent/MX2024002465A/es unknown
- 2022-08-31 EP EP22863498.6A patent/EP4396180A4/en active Pending
- 2022-08-31 WO PCT/CN2022/116084 patent/WO2023030363A1/en not_active Ceased
- 2022-08-31 CN CN202280058535.7A patent/CN118215660A/zh active Pending
- 2022-08-31 KR KR1020247010341A patent/KR20240054327A/ko active Pending
- 2022-08-31 CA CA3230314A patent/CA3230314A1/en active Pending
- 2022-08-31 JP JP2024513277A patent/JP2024530315A/ja active Pending
- 2022-08-31 IL IL311106A patent/IL311106A/en unknown
- 2022-08-31 AU AU2022336557A patent/AU2022336557A1/en active Pending
-
2024
- 2024-02-27 US US18/589,022 patent/US20240317743A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021521138A (ja) * | 2018-04-29 | 2021-08-26 | ベイジーン リミテッド | Bcl−2阻害剤 |
Non-Patent Citations (6)
| Title |
|---|
| C.G.WERMUTH編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005866645 * |
| CAIRA, M.R.: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, JPN6014016881, 1998, pages 163 - 208, ISSN: 0005866642 * |
| 化学実験操作法 上巻, JPN6010029432, 1963, pages 371 - 399, ISSN: 0005866643 * |
| 医薬品の残留溶媒ガイドラインについて, JPN6023047248, 1998, ISSN: 0005866646 * |
| 平山令明, 有機化合物結晶作製ハンドブック, JPN6014022315, 2008, pages 10 - 11, ISSN: 0005866641 * |
| 橋田 充, 経口投与製剤の設計と評価, JPN6008031302, 10 February 1995 (1995-02-10), pages 76 - 79, ISSN: 0005866644 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3230314A1 (en) | 2023-03-09 |
| US20240317743A1 (en) | 2024-09-26 |
| WO2023030363A1 (en) | 2023-03-09 |
| TW202328125A (zh) | 2023-07-16 |
| EP4396180A4 (en) | 2025-07-09 |
| CN118215660A (zh) | 2024-06-18 |
| MX2024002465A (es) | 2024-04-29 |
| EP4396180A1 (en) | 2024-07-10 |
| AU2022336557A1 (en) | 2024-03-21 |
| IL311106A (en) | 2024-04-01 |
| KR20240054327A (ko) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20260041111A (ko) | 아다그라시브 염의 결정질 형태 | |
| TWI526440B (zh) | 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{(6-[4-(4-乙基-六氫吡-1-基)-苯胺基]-吡啶-4-基}-1-甲基尿素之結晶型及其鹽 | |
| KR102618114B1 (ko) | 이브루티닙과 카복실산의 공결정체 | |
| US20140343087A1 (en) | Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
| EP2970123B2 (en) | Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation | |
| JP7314319B2 (ja) | Cdk9阻害剤の結晶多形体及びその製造方法と用途 | |
| EP3205653B1 (en) | Crystal form of bisulfate of jak inhibitor and preparation method therefor | |
| CN108779126A (zh) | 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式 | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| US20240317743A1 (en) | Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof | |
| ES2814499T3 (es) | Formas en estado sólido de sales de Nilotinib | |
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| JP2016512518A (ja) | ベムラフェニブ塩酸塩の固体形態 | |
| US20190016718A1 (en) | Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof | |
| CA3041134A1 (en) | Novel salts of nilotinib and crystalline forms thereof | |
| US20220002302A1 (en) | Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor | |
| CN114026088A (zh) | Jak2抑制剂的结晶形式 | |
| JP6656505B2 (ja) | オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法 | |
| KR20060080817A (ko) | 시부트라민의 디카복실산염 | |
| HK40106793A (en) | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof | |
| WO2022224269A1 (en) | Co-crystals, salts and solid forms of niraparib | |
| TWI846516B (zh) | Cdk9抑制劑的多晶型物及其製法和用途 | |
| EP3517529B1 (en) | Salt of quinazoline derivative, preparation method therefor and application thereof | |
| KR20240146734A (ko) | 피마살탄의 신규 염 및 이의 제조방법 | |
| HK40111611A (zh) | 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20250106 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250826 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250826 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260525 |